Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The event is scheduled to take place in New York on Monday, September 30, 2024. Dyne's management team will engage in a fireside chat at 2:00 p.m. ET.
The company, which focuses on developing innovative life-transforming therapeutics for people with genetically driven diseases, will provide a live webcast of the presentation. Interested parties can access the webcast through the Investors & Media section of Dyne's official website. For those unable to attend the live event, a replay will be available for 90 days following the presentation.
Dyne Therapeutics (Nasdaq: DYN), un'azienda in fase clinica specializzata nelle malattie muscolari, ha annunciato la sua partecipazione alla 8ª Conferenza Annuale sui Farmaci Genetici di Chardan. L'evento si svolgerà a New York lunedì 30 settembre 2024. Il team dirigenziale di Dyne parteciperà a un fireside chat alle 14:00 ET.
L'azienda, che si concentra sullo sviluppo di terapie innovative in grado di trasformare la vita per persone affette da malattie di origine genetica, offrirà un webcast in diretta della presentazione. Le parti interessate possono accedere al webcast tramite la sezione Investitori & Media del sito ufficiale di Dyne. Per coloro che non possono partecipare all'evento dal vivo, sarà disponibile una registrazione per 90 giorni dopo la presentazione.
Dyne Therapeutics (Nasdaq: DYN), una empresa en etapa clínica especializada en enfermedades musculares, ha anunciado su participación en la 8ª Conferencia Anual de Medicinas Genéticas de Chardan. El evento está programado para llevarse a cabo en Nueva York el lunes 30 de septiembre de 2024. El equipo directivo de Dyne participará en una charla fireside a las 2:00 p.m. ET.
La empresa, que se centra en el desarrollo de terapias innovadoras que transforman la vida para personas con enfermedades de origen genético, ofrecerá un webcast en vivo de la presentación. Las partes interesadas pueden acceder al webcast a través de la sección Inversores & Medios del sitio web oficial de Dyne. Para aquellos que no puedan asistir al evento en vivo, habrá una repetición disponible durante 90 días después de la presentación.
Dyne Therapeutics (Nasdaq: DYN), 임상 단계의 근육 질환 회사가 Chardan의 제8회 연례 유전자 의학 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 30일 월요일 뉴욕에서 개최될 예정입니다. Dyne의 경영진은 오후 2시 ET에 파이어사이드 채트에 참여할 것입니다.
이 회사는 유전자에 의해 유발된 질환을 가진 사람들을 위한 혁신적인 삶을 변화시키는 치료제를 개발하는 데 주력하고 있으며, 프레젠테이션의 라이브 웹캐스트를 제공합니다. 관심 있는 분들은 Dyne 공식 웹사이트의 투자자 및 미디어 섹션을 통해 웹캐스트에 접속할 수 있습니다. 라이브 이벤트에 참석할 수 없는 분들을 위해 프레젠테이션 후 90일 동안 재생 가능한 재방송도 제공됩니다.
Dyne Therapeutics (Nasdaq: DYN), une entreprise en phase clinique spécialisée dans les maladies musculaires, a annoncé sa participation à la 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan. L'événement est prévu pour le lundi 30 septembre 2024 à New York. L'équipe de direction de Dyne participera à une discussion informelle à 14h00 ET.
L'entreprise, qui se concentre sur le développement de thérapies innovantes pouvant transformer la vie des personnes atteintes de maladies d'origine génétique, proposera un webcast en direct de la présentation. Les personnes intéressées peuvent accéder au webcast via la section Investisseurs & Médias du site officiel de Dyne. Pour ceux qui ne peuvent pas assister à l'événement en direct, une retransmission sera disponible pendant 90 jours après la présentation.
Dyne Therapeutics (Nasdaq: DYN), ein Unternehmen in der klinischen Phase für Muskelerkrankungen, hat seine Teilnahme an der 8. Jahreskonferenz für Genetik-Medikamente von Chardan angekündigt. Die Veranstaltung findet am Montag, den 30. September 2024 in New York statt. Das Management-Team von Dyne wird an einem Fireside-Chat um 14:00 Uhr ET teilnehmen.
Das Unternehmen, das sich auf die Entwicklung innovativer, lebensverändernder Therapien für Menschen mit genetisch bedingten Krankheiten konzentriert, wird ein Live-Webcast der Präsentation anbieten. Interessierte können über den Bereich Investoren & Medien auf der offiziellen Website von Dyne auf den Webcast zugreifen. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird eine Wiederholung für 90 Tage nach der Präsentation verfügbar sein.
- None.
- None.
WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
When and where is Dyne Therapeutics (DYN) presenting at Chardan's Genetic Medicines Conference?
How can I watch Dyne Therapeutics' (DYN) presentation at the Chardan conference?
How long will the replay of Dyne Therapeutics' (DYN) Chardan conference presentation be available?
What is the focus of Dyne Therapeutics (DYN) as a company?
